- Home
- » Tags
- » Netoglitazone
Top View
- Pharmaabkommen A1 E
- Synthetic and Natural Peroxisome Proliferator‑Activated Receptor (PPAR) Agonists As Candidates for the Therapy of the Metabolic Syndrome
- Customs Tariff - Schedule Xxi - 1
- Ep 1 599 469 B1
- Role of Peroxisome Proliferator-Activated Receptors (Ppars) in Trophoblast Functions
- INFLAMMATORY BOWEL DISEASE MONITOR Commentary and Analysis on Advances in the Understanding and Management of Inflammatory Bowel Disease
- Supplementary Materials: Building and Testing Pparγ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain
- Fibrates, Glitazones and Peroxisome Proliferator-Activated Receptors Fanny Lalloyer1,2,3,4 and Bart Staels1,2,3,4
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
- Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
- Approach to a Safer Insulin Sensitizer
- Review Article
- Quantitative Structural Assessment of Graded Receptor Agonism
- Review Article Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Recent Advances in Diabetes Mellitus
- Molecular Modeling Study of Pparγ Agonists: Dehydro-Di-Isoeugenol, Macelignan, Pioglitazone, Netoglitazone, and Rosiglitazone As Antidiabetic Drugs